NCT01749904View on ClinicalTrials.gov

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 2, 2015

Study Completion Date

September 30, 2015

Conditions
Open-Angle GlaucomaOcular Hypertension
Interventions
DRUG

BOL-303259-X

Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).

DRUG

Timolol

Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)

DRUG

BOL-303259-X

All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)

Trial Locations (1)

14609

Bausch & Lomb Inc., Rochester

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT01749904 - Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter